Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions.

Autor: van Overbeeke E; Clinical Pharmacology and Pharmacotherapy, University of Leuven, Herestraat 49 Box 521, 3000 Leuven, Belgium. Electronic address: eline.vanoverbeeke@kuleuven.be., Michelsen S; Clinical Pharmacology and Pharmacotherapy, University of Leuven, Herestraat 49 Box 521, 3000 Leuven, Belgium; Healthcare Management Centre, Vlerick Business School, Reep 1, 9000 Ghent, Belgium., Toumi M; Public Health Department, Aix Marseille University, 27 bd Jean Moulin, Marseille, France., Stevens H; Institute for Interdisciplinary Innovation in Healthcare (I(3)h), Université libre de Bruxelles, Route de Lennik 808, Brussels, Belgium., Trusheim M; Massachusetts Institute of Technology, 100 Main Street, Cambridge, MA 02139, USA., Huys I; Clinical Pharmacology and Pharmacotherapy, University of Leuven, Herestraat 49 Box 521, 3000 Leuven, Belgium., Simoens S; Clinical Pharmacology and Pharmacotherapy, University of Leuven, Herestraat 49 Box 521, 3000 Leuven, Belgium.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2021 Feb; Vol. 26 (2), pp. 399-415. Date of Electronic Publication: 2020 Nov 24.
DOI: 10.1016/j.drudis.2020.11.024
Abstrakt: This review can inform gene therapy developers on challenges that can be encountered when seeking market access. Moreover, it provides an overview of trends among challenges and potential solutions.
(Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: